Loading...

Revolutionizing the understanding of treatment response to improve patient outcomes

AIQ ANNOUNCEMENTS

October 7, 2020
Flywheel and AIQ Solutions recently announced a partnership to offer a data management and analysis solution to increase clinicians’ and researchers’ understanding of treatment response for complex diseases that include the largest research area of oncology. The combination of Flywheel’s cloud-scale data management and collaboration platform along with the powerful AIQ technology will provide a scalable solution for improved patient management and the overall delivery of accurate data for the therapeutic area.

Delivering actionable intelligence that enhances understanding of treatment response for complex diseaseS 

The AIQ Solutions medical software platform allows researchers to understand disease better and clinicians to manage patients more effectively.

Incomplete treatment response information can lead to ineffective therapy choices

LEARN MORE

Heterogeneity understood through AIQ Solutions intelligence

We provide detailed information highlighting treatment response heterogeneity to build a comprehensive Treatment Response Assessment.
LEARN MORE
1

Improve patient
management

Optimize therapy through early identification of sub-optimal treatment response and direct targeting of treatment resistance.
2

Reduce healthcare costs associated with INeffective treatments

Extend benefit of effective therapies, avoid unnecessary use of expensive combination therapies, and reduce spending on ineffective therapies.
3

Streamline drug development

Make more efficient go/no-go decisions by better understanding pharmacodynamic effects and mechanisms of resistance in shorter, smaller studies.

AIQ technology can be applied in a broad range of clinical scenarios

Below are a few examples of how our treatment response assessments have been applied.

Type of therapy

- Immunotherapy    
- Targeted radionuclide therapy
- Chemotherapy
- Hormone-receptor targeting  
- Theranostics

DISEASE Type

- Metastatic prostate cancer 
- Metastatic breast cancer 
- GI neuroendocrine tumors
- Metastatic melanoma
- Osteoporosis
- Leukemia/ Hematologic Cancers

SITE OF METASTAsIS

- Bone    
- Liver    
- Lung    
- Lymph nodes

Types of scans/tracers

- NaF
- Gallium (Ga)-DOTATATE
- FDG
- FLT

organs for toxicity

- Liver
- Kidney
- Colitis

Learn more about AIQ

For more information on AIQ treatment response solutions

Contact our Team
PAGE CITATIONSOUr Productclinical studiespatient managementPARTNERSHIPSAbout usresources
Copyright © 2020, AIQ Global, Inc. All Rights Reserved.

Per the US FDA, AIQ technology is indicated for use in the identification, quantification, and evaluation of Regions of Interest (ROIs) from digital medical images, including PET and CT. Any other applications of AIQ technology are for research purposes only.